New eye drug hopes to slow inherited blindness

NCT ID NCT06970106

Recruiting now Disease control Sponsor: PYC Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times

Summary

This early-stage study tests a new medicine called PYC-001, given as an injection into the eye, for people with a rare genetic eye disease (autosomal dominant optic atrophy) caused by a change in the OPA1 gene. The main goal is to check the safety of different doses and schedules in about 18 adults from Australia, New Zealand, and other APAC countries. Researchers will also look at whether the treatment can help preserve or improve vision.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOSOMAL DOMINANT OPTIC ATROPHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autosomal dominant optic atrophy autosomal dominant optic atrophy, classic form hereditary optic atrophy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTOSOMAL DOMINANT OPTIC ATROPHY HEREDITARY OPTIC ATROPHIES KJER OPTIC ATROPHY OPA1 GENE MUTATION

Contacts and locations

Locations

Cerulea Clinical Trials
RECRUITING

East Melbourne, Australia
Retina Specialists
RECRUITING

Auckland, 1052, New Zealand
Save Sight Institute - Sydney Eye Hospital
RECRUITING

Sydney, New South Wales, 2000, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.